https://www.selleckchem.com/pr....oducts/empagliflozin
Hepatic encephalopathy (HE) is associated with marked increases in morbidity and mortality for patients with cirrhosis. We aimed to determine the risk of and predictors for HE in contemporary patients. We prospectively enrolled 294 subjects with Child A-B (70% Child A) cirrhosis and portal hypertension without previous HE from July 2016 to August 2018. The primary outcome was the development of overt HE (grade 2). We assessed the predictive power of model for end-stage liver disease-sodium (MELD-Na) score, the Inhibito
Like
Comment
Share
